Gilead Sciences, Inc. GILD
Gilead Sciences, Inc. is a global biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need. The company primarily focuses on developing and marketing therapeutics for life-threatening diseases, with core strengths in virology and oncology. Its product portfolio includes treatments for HIV, viral hepatitis, influenza, COVID-19, and various cancers, utilizing advanced therapeutic approaches such as small molecules, cell therapies, and antibody-drug conjugates. Gilead serves healthcare providers and patients worldwide through a direct commercial infrastructure, generating revenue primarily from product sales of its approved medicines. The company operates a research-driven business model that involves significant investment in clinical development, strategic collaborations, and acquisitions to expand its pipeline and address serious health challenges.
LSTM Forecast
Forecast model is not trained yet for this market.
Train and backfill the LSTM forecast to surface a directional view here.